Streetwise Regenerative Medicine Articles


Stock-Moving Catalysts Anticipated for Regeneus in Q4/16

Source: The Life Sciences Report  (09/28/2016)
Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. read more >

Regeneus Secures Government Funding for R&D

Source: The Life Sciences Report  (09/14/2016)
Regeneus Secures Government Funding for R&D
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. read more >

Investment in Cell and Gene Therapies Ramps Up

Source: George S. Mack of The Life Sciences Report  (06/08/2016)
Investment in Cell and Gene Therapies Ramps Up
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. read more >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Source: George S. Mack of The Life Sciences Report  (05/11/2016)
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Unmet medical needs exist all over the globe, creating a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare analyst Dennis Hulme of Edison Investment Research cites a group of Australian medtech and biotech names that investors should look at very carefully. read more >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer

Source: George S. Mack of The Life Sciences Report   (04/20/2016)
What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease. In this interview, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to extend the lives of thousands of men. read more >

Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update

Source: Tracy Salcedo of The Life Sciences Report  (03/09/2016)
Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist. read more >

Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital

Source: George S. Mack of The Life Sciences Report  (03/02/2016)
Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Eden Rahim of Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks. read more >

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma

Source: George S. Mack of The Life Sciences Report  (02/17/2016)
Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma
The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. Wijma applies his small-cap expertise to shed light on overlooked biotechs from Canada, Europe and Australia that could bring huge returns to investor portfolios. read more >

Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw

Source: George S. Mack of The Life Sciences Report  (02/10/2016)
Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw
Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview, the former big pharma researcher details four growth names that could follow in the footsteps of previous winners. read more >

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell

Source: George S. Mack of The Life Sciences Report  (02/03/2016)
Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Canada encompasses healthcare-related businesses that are generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios: He knows both spheres, and as a hedge fund and mutual fund manager he has made a specialty in acquisitions of cash-generating healthcare companies. read more >
Management Q&A: View from the Top

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

Managment Q&A: View from the Top
Source: Peter Byrne of The Life Sciences Report  (02/03/2016)
Stewart Washer
In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. read more >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase

Source: Tracy Salcedo of The Life Sciences Report  (01/27/2016)
The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. read more >

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News

Source: George S. Mack of The Life Sciences Report  (01/20/2016)
The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. read more >

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist

Source: Staff of The Life Sciences Report  (12/15/2015)
Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year. read more >

Regenerative Medicine Follows the CAR T-Cell Gravy Train: Maxim Group's Jason Kolbert and Jason McCarthy

Source: George S. Mack of The Life Sciences Report  (12/02/2015)
Regenerative Medicine Follows the CAR T-Cell Gravy Train: Maxim Group's Jason Kolbert and Jason McCarthy
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer, tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives. read more >

Raymond James Analyst Reni Benjamin: Regenerating Portfolios with Cell Therapies, Antibodies and Small Molecules

Source: George S. Mack of The Life Sciences Report  (11/04/2015)
Raymond James Analyst Reni Benjamin: Regenerating Portfolios with Cell Therapies, Antibodies and Small Molecules
Reni Benjamin of Raymond James outlines the groundbreaking work being done by a number of new-era biotech companies with the potential to return multiples on investment over the next two to three years. read more >

Advocacy and Technology Move Stem Cell Research Forward

Source: Dan Levy of The Life Sciences Report  (10/07/2015)
Advocacy and Technology Move Stem Cell Research Forward
Until recently, progress in the regenerative medicine universe has been hampered by political and medical ethics arguments. Those brakes are now off, and Bernie Siegel of the Genetics Policy Institute elaborates on how the science may soon facilitate revolutionary cures... read more >
Management Q&A: View from the Top

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level

Managment Q&A: View from the Top
Source: Gail Dutton of The Life Sciences Report  (09/30/2015)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials. read more >

CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays

Source: Gail Dutton of The Life Sciences Report  (09/09/2015)
CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays
CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work ahead. Alan Leong, senior analyst with BioWatch, describes how some CAR T-cell companies are hedging their bets by also developing bispecific antibodies, and discusses the growing excitement in the regenerative medicine space. read more >

Regenerative Medicine in Japan: CJ PARTNERS' Colin Lee Novick

Source: Gail Dutton of The Life Sciences Report  (08/05/2015)
Regenerative Medicine in Japan: CJ PARTNERS' Colin Lee Novick
Colin Lee Novick, managing partner with CJ PARTNERS, describes Japan's regenerative medicine frontier and lists investment-worthy companies that are pushing the boundaries. read more >

Alabama Institute of Medicine's Tory Williams Unites Patient Advocacy with Stem Cell Funding in the Deep South

Source: Gail Dutton of The Life Sciences Report  (04/29/2015)
Alabama Institute of Medicine's Tory Williams Unites Patient Advocacy with Stem Cell Funding in the Deep South
Tory Williams of the Alabama Institute of Medicine describes how her patient advocacy group is working with research institutes to advance stem cell science and provide the early-stage funding and contacts that researchers and young companies need to grow and prosper. read more >

How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM

Source: George S. Mack of The Life Sciences Report  (04/23/2015)
How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM
Centre for Commercialization of Regenerative Medicine President and CEO Michael May unwraps process that brings ideas out of academia and enables startups to get new regenmed technologies into commercial development. read more >

Where Do Cures Reside? Morrie Ruffin and Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine

Source: George S. Mack of The Life Sciences Report  (01/08/2015)
Where Do Cures Reside? Morrie Ruffin and Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine
Revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones—and investors in the space should strap in for a rewarding joy ride. Alliance for Regenerative Medicine cofounders Morrie Ruffin and Michael Werner consider how new federal guidance might enable new standards of care in cardiovascular, neurologic and oncologic medicine. read more >

Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler

Source: George S. Mack of The Life Sciences Report  (10/22/2014)
Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview, former regenerative medicine consultant R. Lee Buckler talks about Japan's hospitable stance on proposed cell therapies. read more >

Regenerative Medicine Finally Gets Some Respect: Reni Benjamin

Source: JT Long of The Life Sciences Report  (02/11/2014)
including Regenerative Medicine Finally Gets Some Respect: Reni Benjamin read more >
Showing Results: 26 to 50 of 55 Prev Next

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe